Hot off the press in Nature! After 10 years, 2,780 patients and 300+ scientists, today we announce the Human Cancer Models Initiative (HCMI) release of 665 organoids and other next generation models! All models and data available to accelerate cancer drug discovery! @nature.com rdcu.be/fx3I3

A compendium of next-generation patient-derived models for diverse cancers

Nature - The international collaboration of the Human Cancer Models Initiative presents a comprehensive resource of next-generation cancer models from 2,780 donors with 25 cancer types and...

rdcu.be

Next-generation patient-derived models for diverse cancers @nature.com @broadinstitute.org @boehmjesse.bsky.social @sangerinstitute.bsky.social www.nature.com/articles/s41... www.nature.com/articles/s41... www.nature.com/articles/s41...

Very excited to be part of this massive effort to characterize cancer models, revealing strong epigenetic concordance between primary tumors and matched cancer models. rdcu.be/fx3I3

A compendium of next-generation patient-derived models for diverse cancers

Nature - The international collaboration of the Human Cancer Models Initiative presents a comprehensive resource of next-generation cancer models from 2,780 donors with 25 cancer types and...

rdcu.be

www.vai.org/article/comp...

Compendium of patient-derived models offers new opportunities for cancer research, precision oncology – Van Andel Institute

Read about Compendium of patient-derived models offers new opportunities for cancer research, precision oncology on Van Andel Institute – Stay updated on the latest research and groundbreaking discove...

vai.org

The Cancer Dependency Map now includes data from dozens of 3D cancer models across 10 cancer types, revealing new dependencies and offering a more comprehensive resource for cancer research.

Cancer Dependency Map now includes next-generation 3D cancer models

Broad scientists expand the DepMap by adding cancer organoids and demonstrate the models’ potential to fuel new discoveries.

broad.io

@boehmjesse.bsky.social will discuss functional precision medicine while also highlighting how Break Through Cancer's model of radical collaboration is helping accelerate progress toward better treatments for patients. Read more about the workshop here: events.cancer.gov/OD/functiona...

Functional precision medicine has enormous potential to improve how we match the right cancer therapies to the right patients. This week, our Chief Scientific Officer @boehmjesse.bsky.social is participating in the National Cancer Institute's Precision in Practice workshop

Congratulations to @boehmjesse.bsky.social, our Chief Science Officer, and @broadinstitute.org's DepMap team on their 2026 @theaacr.bsky.social Scientific Achievement Award. This team is honored for systematically mapping genetic dependencies across cancer cells to uncover specific vulnerabilities

𝖡𝗋𝖾𝖺𝗄 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝖢𝖺𝗇𝖼𝖾𝗋 and our president Tyler Jacks are featured in @cancerletter.com today. The story highlights our model of Radical Collaboration™ and how we’re aligning institutions and scientists to accelerate progress against the deadliest cancers. cancerletter.com/conversation...

Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.” - The Cancer Letter

Five years ago, Tyler Jacks took on a new challenge, becoming president of Break Through Cancer, a foundation that has pledged to spend at least $500 million to support research projects across top ti...

cancerletter.com

As we mark five years of Break Through Cancer, we’re posting here for the first time! Five years ago, we asked: What would cancer research look like if collaboration was built into the design? #RadicalCollaboration™ is our answer. These numbers reflect the scale

Both chambers of Congress have now passed the FY26 minibus with NIH provisions. The President will sign. (1) $48.7 billion for NIH (2) Full IDC recovery (3) No more multi-year funding (4) No NIH reorganization, maintaining the current IC structure.

We are excited to join The Mark Foundation for Cancer Research, Lustgarten Foundation, Break Through Cancer, and Tina's Wish in a collaboration to solve the critical problem of early detection and diagnosis for some of the world’s deadliest cancers. buff.ly/EAA0knn

Long time off this platform.. excited to be back to share that I have been elected President of the @thesfpm.bsky.social alongside @boehmjesse.bsky.social. This community has been a true home for those of us for whom patient-derived models and functional testing belong at the center of cancer care/n

Great to hear Iain Foulkes join @break-cancer.bsky.social's @boehmjesse.bsky.social, @su2c.bsky.social's Julian Adams & NUT Carcinoma Alliance's Maddie Musselman at @milkeninstitute.org #MIHealthSummit to discuss how global collaboration can drive innovation in cancer research #CancerGrandChallenges

It was a great discussion! There has never before been so much opportunity to work together to solve the major challenges of our field.

@su2cscience.bsky.social · 9mo ago

Dr. Julian Adams, President and CEO of @su2c.bsky.social, is at the @milkeninstitute.org today discussing innovations in #EarlyDetection and equitable cancer care. Panelists include @boehmjesse.bsky.social from @break-cancer.bsky.social, Ian Foulkes from @cancerresearchuk.org, and Maddie Musselman

We are very proud of our Accelerating GBM Therapies TeamLab for this outstanding, potentially field changing work. We must sample continuously to understand hidden, temporal responses to therapy. Even in the brain.

Science Magazine@science.org · 10mo ago

Researchers have applied serial biopsies to safely monitor glioblastoma progression and responses to immunotherapy in two patients, capturing details that are invisible to standard-of-care MRI. Learn more in #ScienceTranslationalMedicine: https://scim.ag/46Id31J

Excited to get this out there as we go through revisions. These findings have changed how I think about KIAA1549-BRAF of pediatric gliomas, and all other fusions, completely. The fusion partner is important, necessary and engenders novel vulnerabilities that can be therapeutically targeted.

Adnan Halim@handle.invalid · 12mo ago

Together with @glyco.me, @bandolab.bsky.social and teams, we recently uncovered a link between pediatric brain tumors, POMT1/2 enzymes and KIAA1549 - full story in the preprint below: www.biorxiv.org/content/10.1...

Be sure to catch Jesse Boehm @boehmjesse.bsky.social in the Tumoroids, Organoids, and Cell Culture session at #AACR25! He’ll present how patient-derived cancer models are shaping research on rare and understudied cancers. 🔗 www.abstractsonline.com/pp8/#!/20273...

Today marks the beginning of OpenRxiv, which replaces bioRxiv and medRxiv, the world's largest preprint platform for life and medical science openrxiv.org/introducing-... @openrxiv.bsky.social

Research support for rare diseases, which cumulatively affect ~30 million Americans, is primarily derived from NIH. Such work is exemplified by Prof Anna Greka @broadinstitute.org in a new Ground Truths podcast. Open-access, w/ transcript, video, no ads erictopol.substack.com/p/anna-greka...

Anna Greka: Molecular Sleuthing for Rare Diseases

Listen now | Finding the Mechanisms and the Basis for Potential Cures

erictopol.substack.com

3 points of progress vs pancreatic cancer! 1. Neoantigen vaccines www.nature.com/articles/s41... 2. KRAS drugs www.wsj.com/health/healt... 3. Early diagnosis www.science.org/doi/10.1126/...

Francis Collins, the NIH Director for 12 years, led the Human Genome Project and other NIH efforts for 32 years, resigned today. Key words from his resignation letter www.nytimes.com/2025/03/01/u...

“The rare tumor space is an example of where we should think hard about the quality data that we have and how we can help inform future treatments,” @danafarber.bsky.social’s Suzanne George, MD, shared at #RareDiseaseSummit 2025.

Inexplicably, US administration has launched an unprecedented assault on science, on research institutions & on vital international organizations & initiatives. An assault on science anywhere is an assault on science everywhere; the global community must unite 🧪 www.nature.com/articles/d41...

Trump 2.0: an assault on science anywhere is an assault on science everywhere

US President Donald Trump is taking a wrecking ball to science and to international institutions. The global research community must take a stand against these attacks.

nature.com

Excited to be speaking this Tuesday, Feb. 25 at #RareDiseaseSummit 2025, @GlobeEvent’s inaugural summit focused on innovation and advocacy in rare disease, “From Bench to Bedside: Rare Cancer Innovations.” Sign up to join in person or virtually: @bostonglobe.com rarediseasesummit2025.splashthat.com

Exciting new synthetic lethal target emerging from #depmap data 🧪🧬 Frequent passenger mutations in genes involved in mRNA quality control lead to a dependency on PELO-HBS1L Congratulations to the DepMap team! @vazquezf.bsky.social #depmap #cancertarget #syntheticlethal

SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO - Nature

Analysis of large-scale CRISPR screening data, combined with experiments in patient-derived tumour organoid models, identifies PELO as a potential therapeutic target in chromosomal 9p21.3-deleted canc...

nature.com

(1/3) Excited to share our latest work using @depmap.org to uncover a new synthetic lethality in two distinct patient populations! We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO #CancerResearch #SyntheticLethality #Genomics #DepMap

SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO - Nature

Analysis of large-scale CRISPR screening data, combined with experiments in patient-derived tumour organoid models, identifies PELO as a potential therapeutic target in chromosomal 9p21.3-deleted canc...

nature.com

A full attack on US science means the red & blue lines will soon cross. Scientists just want science to progress to help society. This administration - and "Pres Musk" - is telling us they don't need/want US science. We will see many of our great ideas and innovation will go to China and elsewhere